Fulcrum Therapeutics, Inc. FULC R2K
Healthcare · Biotechnology · United States
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
READ MORE ›$6.92
+0.65% 1Y
Market & Price
Market Cap
$461.10M
Current Price
$6.92
High / Low (52W)
$14.60 / $5.91
Beta
3.01
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$5.00
Price to Book
1.38
P/S
-
EV/EBITDA
-1.57
Dividend Yield
-
Profitability & Returns
ROCE
-24.00%
ROE
-27.10%
ROA
-18.36%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.25
EPS (TTM)
$-1.15
Balance Sheet & Liquidity
Debt/Equity
1.76
Quick Ratio
33.97
Current Ratio
34.33
Debt
$5.87M
Total Assets
$366.28M
Current Assets
$357.48M
Working Capital
$344.43M
Ownership
Promoter Holding
3.86%
Chg in Prom Hold
-
FII / Inst Holding
108.04%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$133.65M
Total Revenue (TTM)
-
EBITDA
$-85.18M
Free Cash Flow
$-37.74M
Operating Cash Flow
$-63.56M
Shares Outstanding
66.63M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-33.33%
Profit 5Y
10.62%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- Profit CAGR of 10.6% over 5 years.
CONS
- Revenue declined at -33.3% CAGR over 5 years.
- Trading 52.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FULC Fulcrum Therapeutics, Inc. R2K | 6.92 | - | $461.10M | - | -24.00% | -27.10% | -33.33% | 10.62% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 750.00K | 2.00M | 1.85M | 4.79M | 4.38M | 4.93M | 2.59M | 1.88M | 1.18M | 295.00K | 880.00K | 759.00K | 0 | 80.00M | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.40M | 19.82M | 21.86M | 22.69M | 22.19M |
| Operating Income | - | -7.85M | -9.09M | -37.23M | -13.49M | -17.01M | -18.80M | -15.92M | -19.10M | -17.04M | -19.68M | -20.77M | -26.00M | -34.23M | -24.36M | -27.94M | -27.29M | -27.44M | -29.83M | 52.49M | - | - | -20.40M | -19.82M | -21.86M | -22.69M | -22.19M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.05M | -19.47M | -21.51M | -22.35M | -21.85M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.66M | -17.30M | -19.59M | -20.33M | -18.89M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.94M | -7.85M | -8.94M | -36.84M | -13.17M | -16.54M | -18.45M | -15.69M | -18.96M | -17.00M | -19.65M | -20.72M | -25.93M | -34.07M | -23.74M | -24.78M | -23.78M | -24.02M | -26.87M | 55.41M | - | - | -17.66M | -17.30M | -19.59M | -20.33M | -18.89M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.60 | -0.57 | -0.64 | -0.83 | -0.51 | -0.41 | -0.38 | -0.39 | -0.43 | 0.87 | - | - | -0.28 | -0.28 | -0.31 | -0.31 | -0.25 |
| R&D Expense | - | 5.79M | 6.96M | 34.63M | 10.86M | 13.50M | 14.48M | 12.78M | 15.64M | 16.33M | 17.38M | 17.08M | 17.83M | 25.02M | 15.37M | 16.71M | 17.85M | 18.24M | 19.77M | 17.26M | 14.64M | - | 13.40M | 12.99M | 14.30M | - | 14.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 8.82M | 19.16M | 6.34M | 2.81M | 80.00M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 118.48M | 113.47M | 99.83M | 84.77M |
| Operating Income | -33.50M | -84.22M | -71.61M | -81.05M | -112.13M | -110.66M | -19.83M | -84.77M |
| EBITDA | - | - | - | - | -109.72M | -108.49M | -18.24M | -83.38M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -109.87M | -97.33M | -9.72M | -74.88M |
| Tax Provision | - | - | - | - | - | - | - | - |
| Net Income | -32.59M | -82.68M | -70.82M | -80.85M | -109.87M | -97.33M | -9.72M | -74.88M |
| Diluted EPS | - | - | - | -2.29 | -2.44 | -1.59 | -0.16 | -1.18 |
| R&D Expense | 25.18M | 71.07M | 59.04M | 69.70M | 76.78M | 71.80M | 63.39M | 56.10M |
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 10.62% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +0.65% |
| 6 Months: | -40.03% |
| 3 Months: | -17.42% |
| 1 Month: | -3.22% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 85.77M | 110.44M | 129.58M | - | 226.69M | 257.69M | 260.72M | 366.28M |
| Current Assets | - | - | - | - | - | 207.52M | 242.20M | 249.92M | 357.48M |
| Cash & Equivalents | - | 72.80M | 96.71M | 57.05M | - | 35.10M | 25.56M | 58.21M | 197.53M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 2.50M | 0 | - | - | - |
| Total Liabilities | - | 9.77M | 23.29M | 34.40M | - | 27.74M | 22.50M | 17.68M | 17.28M |
| Current Liabilities | - | 4.23M | 12.14M | 26.73M | - | 16.73M | 13.68M | 11.04M | 13.05M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 13.42M | 10.82M | 8.63M | 6.44M |
| Total Equity | -33.27M | -63.67M | 87.15M | 95.18M | - | 198.94M | 235.19M | 243.03M | 349.00M |
| Shares Outstanding | - | - | - | - | - | 52.10M | 61.92M | 53.97M | 66.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.56M | -39.48M | -53.66M | - | -97.05M | -90.97M | -2.22M | -60.06M |
| Investing Cash Flow | -8.98M | -944.00K | -57.14M | - | 12.41M | -36.69M | 32.23M | 30.72M |
| Financing Cash Flow | 105.03M | 64.34M | 71.13M | - | 84.32M | 118.12M | 2.75M | 168.67M |
| Capital Expenditure | -8.98M | -853.00K | -1.34M | - | -1.96M | -508.00K | -278.00K | -314.00K |
| Free Cash Flow | -31.54M | -40.34M | -55.00M | - | -99.01M | -91.47M | -2.50M | -60.38M |
| Net Change in Cash | - | - | - | - | -314.00K | -9.54M | 32.76M | 139.32M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -811.6% | -423.0% | -1,768.1% | -3,945.2% | -24.8% | - |
| Net Margin % | - | - | -802.7% | -421.9% | -1,732.4% | -3,470.1% | -12.2% | - |
| ROE % | 51.2% | -94.9% | -74.4% | - | -55.2% | -41.4% | -4.0% | -21.5% |
| ROCE % | -41.1% | -85.7% | -69.6% | - | -53.4% | -45.4% | -7.9% | -24.0% |
Shareholding Pattern
Insiders
3.86%
Institutions
108.04%
Public Float
112.38%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.85% | 6.56M | $45.40M |
| 2 | RA Capital Management, L.P. | 9.09% | 6.05M | $41.89M |
| 3 | Blackrock Inc. | 8.09% | 5.39M | $37.30M |
| 4 | TCG Crossover Management, LLC | 7.88% | 5.25M | $36.33M |
| 5 | Braidwell LP | 4.70% | 3.13M | $21.69M |
| 6 | Nantahala Capital Management, LLC | 4.58% | 3.05M | $21.11M |
| 7 | Vanguard Capital Management LLC | 4.04% | 2.69M | $18.64M |
| 8 | Siren, L.L.C. | 3.53% | 2.35M | $16.26M |
| 9 | First Turn Management, LLC | 3.39% | 2.26M | $15.61M |
| 10 | Aberdeen Group plc | 3.32% | 2.21M | $15.31M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FULC
No recent headlines available.